PMGC Holdings (ELAB) Notes Payables (2022 - 2026)

PMGC Holdings (ELAB) posted Notes Payables of $2.5 million for Q1 2026, up 2848.62% sequentially from $85000.0 in Q4 2025.

PMGC Holdings (ELAB) Notes Payables (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Notes Payables for 5 years, with the latest figure at $2.5 million in Q1 2026.

Quarterly Notes Payables changed N/A year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (changed N/A YoY) and the FY2025 annual result came in at $85000.0, changed N/A from the prior year.
Notes Payables improved to $2.5 million in Q1 2026 per ELAB's latest filing, from $85000.0 in the prior quarter.
Over five years, Notes Payables peaked at $519.5 million in Q3 2023 and troughed at $1882.0 in Q3 2024.
A 5-year average of $58.1 million and a median of $94219.0 in 2024 frame the typical range for Notes Payables.
The sharpest annual moves came in 2024 and 2025: Notes Payables plunged 100.0% in 2024, then jumped 36128.37% in 2025.
Over 5 years, Notes Payables stood at $68455.0 in 2022, then surged by 439.27% to $369158.0 in 2023, then sank by 99.49% to $1882.0 in 2024, then jumped by 4416.47% to $85000.0 in 2025, then surged by 2848.62% to $2.5 million in 2026.
According to Business Quant data, Notes Payables over the past three periods registered $2.5 million, $85000.0, and $681818.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	PMGC Holdings	3.01 Mn	-15.78 Mn	385,691.00

Download Data